{"entity":{"id":"socs1","kind":"target","name":"SOCS1","aka":["suppressor of cytokine signaling 1","Suppressor of cytokine signaling 1","SOCS-1","SSI-1","TIP3","Cish1"],"tldr":"SOCS1 (Suppressor of cytokine signalling 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Rectal cancer.","summary":"Essential negative regulator of type I and type II interferon (IFN) signalling, as well as that of other cytokines, including IL2, IL4, IL6 and leukaemia inhibitory factor (LIF). Down-regulates cytokine signalling by inhibiting the JAK/STAT signalling pathway. Acts by binding to JAK proteins and to IFNGR1 and inhibiting their kinase activity.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.49 (direct and indirect evidence; datatypes literature 0.99, animal model 0.51, genetic association 0.04, somatic mutation 0.74). IntOGen calls it a driver in 5 cohorts (3 activating, 2 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma, Rectal Adenocarcinoma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:19383","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19383"},{"label":"UniProt O15524","url":"https://www.uniprot.org/uniprotkb/O15524/entry"},{"label":"NCBI Gene 8651","url":"https://www.ncbi.nlm.nih.gov/gene/8651"},{"label":"Ensembl ENSG00000185338","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185338"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["non-hodgkin-lymphoma","dlbcl","rectal-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"SOCS1","role":["oncogene-driver","tumour-suppressor","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:19383","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19383","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt O15524","url":"https://www.uniprot.org/uniprotkb/O15524/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene SOCS1","url":"https://civicdb.org/features/6856","note":"1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000185338","url":"https://platform.opentargets.org/target/ENSG00000185338/associations","note":"association with cancer (MONDO_0004992) 0.49; per-cancer scores at or above 0.5: diffuse large B-cell lymphoma 0.63, non-Hodgkin lymphoma 0.68 (GraphQL API, CC0)"},{"label":"IntOGen SOCS1","url":"https://www.intogen.org/search?gene=SOCS1","note":"driver in 5 cohorts (Act 3, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:19383","ensembl":"ENSG00000185338","uniprot":"O15524","entrez":"8651","biology":"Essential negative regulator of type I and type II interferon (IFN) signalling, as well as that of other cytokines, including IL2, IL4, IL6 and leukaemia inhibitory factor (LIF). Down-regulates cytokine signalling by inhibiting the JAK/STAT signalling pathway. Acts by binding to JAK proteins and to IFNGR1 and inhibiting their kinase activity. In vitro, suppresses Tec protein-tyrosine activity. Regulates IFN-gamma (IFNG)-mediated sensory neuron survival. Probable substrate recognition component of an ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Location: Nucleus; Cytoplasmic vesicle (UniProt). Locus 16p13.13 (HGNC).","whereFound":["Non-Hodgkin lymphoma: Open Targets association 0.68 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL)","Diffuse large B-cell lymphoma: Open Targets association 0.63 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease","Rectal cancer: IntOGen driver in 1 cohort (READ)"],"targetClass":"oncogene","prevalence":[]},"route":"/targets/socs1/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}]}}